10-Q: Intuitive Surgical Reports Strong Q2 Growth Amidst Margin Pressures and Tariff Headwinds

Intuitive Surgical, Inc. announced robust revenue and procedure growth for the second quarter of 2025, driven by increased system placements and procedure volumes, though gross profit margins faced pressure from new product launches and tariffs.

Summary

• Total revenue increased by 21% to $2.44 billion for the three months ended June 30, 2025, compared to $2.01 billion for the same period in 2024.
• Net income attributable to Intuitive Surgical, Inc. grew 25% to $658.4 million for the second quarter of 2025, up from $526.9 million in Q2 2024.
• Diluted earnings per share (EPS) rose 24% to $1.81 for Q2 2025, compared to $1.46 in Q2 2024.
• Approximately 775,000 da Vinci procedures were performed in Q2 2025, a 17% increase from 661,000 procedures in Q2 2024, driven by U.S. general surgery and OUS general surgery and urology.
• Ion procedures increased by 52% to 35,300 in Q2 2025, up from 23,200 in Q2 2024.
• The company placed 395 da Vinci surgical systems in Q2 2025, an increase from 341 systems in Q2 2024, including 180 da Vinci 5 systems.
• The da Vinci surgical system installed base reached approximately 10,488 systems as of June 30, 2025, a 14% increase year-over-year.
• Gross profit margin decreased to 66.3% in Q2 2025 from 68.3% in Q2 2024, primarily due to higher costs associated with the da Vinci 5 launch, new tariffs, and increased fixed overhead.
• Cash, cash equivalents, and investments totaled $9.53 billion as of June 30, 2025, an increase of $0.70 billion from December 31, 2024.

Sentiment

Score: 7

Explanation: The company delivered strong top-line and bottom-line growth, driven by robust procedure adoption and system placements, particularly for its new da Vinci 5 system. This indicates healthy demand for its innovative products. However, the decline in gross profit margins due to new product launch costs and anticipated significant increases in cost of revenues from tariffs present notable headwinds. While the core business is performing well, these margin pressures and increasing competition in key markets like China introduce a degree of caution.

Positives

• Total revenue increased by 21% for the three months ended June 30, 2025, demonstrating strong top-line growth.
• Net income attributable to Intuitive Surgical, Inc. grew 25% to $658.4 million in Q2 2025, reflecting improved profitability.
• Da Vinci procedure volume increased by 17% globally, with strong growth in U.S. general surgery and OUS general surgery and urology, indicating continued adoption.
• Ion procedure volume surged by 52%, driven by a larger installed base and conversion from other lung biopsy modalities.
• Da Vinci system placements increased by 16% to 395 systems in Q2 2025, including significant placements of the next-generation da Vinci 5 system (180 units).
• The da Vinci installed base expanded to approximately 10,488 systems, reinforcing the company's market presence.
• Da Vinci surgical system utilization increased by 2% relative to Q2 2024, showing efficient use of installed systems.
• The da Vinci surgical system average selling price (ASP) increased to approximately $1.50 million in Q2 2025, driven by favorable product mix including da Vinci 5 placements.
• The company obtained several new regulatory clearances for its da Vinci 5 system (Japan, EU MDR), Vessel Sealer Curved, SP SureForm 45 staplers (FDA, South Korea, Japan), and extended uses for Ion catheter instrument (EU MDR, FDA).
• The Board of Directors increased the common stock repurchase program authorization to $4.0 billion in May 2025, signaling confidence in financial strength.
• A court found in the company's favor on all antitrust claims in the SIS commercial litigation, staying counterclaims.

Negatives

• Gross profit margin declined to 66.3% in Q2 2025 from 68.3% in Q2 2024, primarily due to higher costs associated with the da Vinci 5 launch, new tariffs, and incremental fixed overhead.
• Ion system placements decreased to 54 systems in Q2 2025 from 74 systems in Q2 2024, as U.S. customer focus shifts from capacity to utilization.
• U.S. da Vinci bariatric procedures declined in the high-single digits in Q2 2025.
• Unrealized losses on strategic investments partially offset interest and other income, net, for the three and six months ended June 30, 2025.
• The effective tax rate for Q2 2025 increased to 20.2% from 18.8% in Q2 2024, primarily due to a lower tax rate benefit from excess tax benefits and lower federal research and development credit benefits.
• Anticipates a 'significant increase' in cost of revenues for the second half of 2025 due to announced and implemented global tariffs.
• Hospital staffing shortages and financial pressures are expected to lead to continued cautious capital spending by customers.

Risks

• Macroeconomic and geopolitical factors, including tariffs, trade barriers, supply chain challenges, inflationary pressures, elevated interest rates, and commodity market disruptions, could materially adversely affect future results and liquidity.
• Increased U.S. import tariffs and reciprocal measures by other countries are expected to increase the cost of raw materials and finished goods, and suppliers may pass on incremental tariff-related costs.
• Delays in obtaining new product approvals, clearances, or certifications from regulatory authorities (e.g., FDA, EU MDR) could extend timelines for new product introductions.
• Inability to comply with complex FDA and other regulations may result in significant enforcement actions.
• Healthcare reform legislation in the U.S. and changes in hospital admissions or payer actions to limit surgical procedures could impact business.
• The timing and success of product development and customer acceptance of new products are uncertain, with risks of quality or other defects in early stages of introduction.
• Disruptions to the supply chain, including difficulties in obtaining sufficient materials or insolvency of soleand single-sourced suppliers, could impact operations.
• Adverse publicity regarding the company, product safety, or adequacy of training could damage reputation and reduce revenue.
• Changes to tax legislation, guidance, and interpretations could impact financial results.
• Third-party remanufactured instruments could result in reduced revenue or generate negative publicity if they cause injuries or malfunction.
• Revenue from usage-based operating lease arrangements can be highly volatile, and there is no guarantee of recuperating leased system costs if utilization falls short of expectations, potentially impacting gross profit margins.
• Exposure to credit losses from lease financing arrangements may increase if customers are adversely affected by economic pressures or changes in healthcare laws/reimbursement.
• System demand in China is adversely impacted by increasing robotic-assisted surgical system competition from domestic companies and a broader central government focus on systematic governance.
• Future sales under China's 14th five-year plan quota are uncertain due to competition and tender processes.
• Significant limits on charges for robotic surgical technology in certain Chinese provinces have impacted procedure volume and instruments and accessories revenue in those areas.
• Increased depreciation expense in 2025 and future periods due to capital expenditures for infrastructure may impact future gross profit margin.
• Unrecognized tax benefits could change due to activities of various tax authorities, affecting the effective tax rate.
• The outcome of income tax audits cannot be predicted with certainty and could require adjustments to the provision for income taxes.
• Ongoing product liability lawsuits allege personal injuries and deaths, with potential for material adverse effects on business, financial condition, or results of operations, and the company is unable to estimate possible loss in excess of the amount recognized.
• Commercial litigation regarding antitrust claims related to EndoWrist service and repair, including a class action, could result in significant losses, and the company is currently unable to make a reasonable estimate of loss.

Future Outlook

The company expects the phased launch of its da Vinci 5 surgical system to extend over several quarters to mature supply and manufacturing processes. It plans to seek additional FDA clearances for da Vinci SP indications and expand its regulatory approvals in OUS markets, as well as expand the da Vinci SP instrument offering. Further, the company intends to seek additional clearances, approvals, and certifications for the Ion endoluminal system in OUS markets. A significant increase in cost of revenues is anticipated for the second half of 2025 due to global tariffs. Customers are expected to remain cautious in capital spending due to staffing shortages and financial pressures. The company plans substantial and increasing investments in research and development and expects capital investments of $650 million to $725 million in 2025, primarily for facilities, funded by cash from operations. OUS procedures and revenue are expected to constitute a larger portion of the business long-term.

Management Comments

• "We believe that minimally invasive care is life-enhancing care."
• "To assure continued alignment with the patients and healthcare community we serve, we have adopted the Quintuple Aim as our north star."
• "We continue to believe that we are well-positioned to synthesize scientific and technological advances in biology, computing, imaging, algorithms, and robotics to deliver meaningful and measurable value to all of our stakeholders."
• "We are in the midst of a phased launch of our da Vinci 5 surgical system, which we expect to extend over several quarters, giving us time to mature our supply and manufacturing processes for the new system."
• "Based on the announced and implemented global tariffs as of the date of this report, and assuming such tariffs remain in place, we anticipate a significant increase in our cost of revenues for the second half of 2025, which will impact our results of operations."
• "We are actively engaged in activities that seek to mitigate the impact of any supply chain risks and disruptions on our operations."
• "We expect that our OUS procedures and revenue will make up a greater portion of our business in the long term."
• "We expect to continue to make substantial investments in research and development and anticipate that research and development expenses will continue to increase in the future."
• "We expect these capital investments to range between $650 million and $725 million in 2025, the majority of which will be facilities-related investments."
• "We intend to fund these capital investments with cash generated from operations."
• "We believe that our current cash, cash equivalents, and investment balances, together with income to be derived from our business, will be sufficient to meet our liquidity requirements for the foreseeable future."

Industry Context

The healthcare industry continues to face challenges globally, including stressed systems, critical resource shortages (e.g., staffing), and demands for lower total cost per patient. The company operates in the context of a shift from traditional open surgery to minimally invasive surgery (MIS), where its da Vinci systems offer advantages. Competition in the robotic-assisted medical procedures field is intensifying, with numerous companies introducing or developing products. Hospitals are experiencing financial pressures from supply chain constraints, inflation, and elevated interest rates, leading to cautious capital spending. Regulatory approval timelines for new medical devices are elongating in key markets like the U.S. and Europe. Specific regional dynamics include increasing competition from domestic companies in China and government-imposed limits on robotic surgical charges in some Chinese provinces, impacting procedure volumes and revenue. In Japan, new da Vinci procedures have gained reimbursement, often at rates comparable to conventional laparoscopic procedures.

Comparison to Industry Standards

• The company's adoption of the 'Quintuple Aim' (better outcomes, patient experience, care team experience, lower cost, expanded access) serves as an internal benchmark for delivering value, aiming to improve upon existing treatment alternatives.
• The da Vinci surgical system is positioned as an advancement over traditional open surgery and conventional MIS, which often result in longer hospitalization and recovery times.
• The company's pricing for da Vinci systems ($0.7 million to $3.1 million) and Ion systems ($500,000 to $815,000) are internal benchmarks for capital equipment investment.
• Lease transactions are stated to generate 'similar gross profit margins' as sale transactions, indicating an internal financial performance comparison.
• The company estimates that penetration of lung biopsy in the U.S. is 'approaching the halfway point,' providing a market penetration benchmark for its Ion system.
• New da Vinci procedures granted reimbursement in Japan are generally reimbursed at rates 'equal to the conventional laparoscopic procedures,' indicating a comparison to established MIS reimbursement standards.
• The company explicitly names numerous competitors in the robotic-assisted medical procedures field, including Beijing Surgerii Robotics Company Limited, CMR Surgical Ltd., Distalmotion SA, Johnson & Johnson, Karl Storz SE & Co. KG, Medicaroid Corporation, Medtronic plc, meerecompany Inc., Noah Medical Corporation, Shandong Weigao Group Medical Polymer Company Ltd., Shanghai Microport Medbot (Group) Co., Ltd., Shenzhen Edge Medical Co., Ltd., and SS Innovations International, Inc., acknowledging a competitive landscape.

Management Changes

Corporate Governance

Legal Proceedings

• The company is a defendant in multiple individual product liability lawsuits alleging personal injuries and deaths from da Vinci surgical system use, with claims including design defects, negligence, fraud, and breach of warranty. The company disputes these allegations and is defending against the claims, but is unable to estimate the possible loss or range of loss in excess of the amount recognized.
• In a patent infringement lawsuit by Rex Medical, L.P., a jury awarded $10 million in damages in October 2022, which was reduced to nominal damages of $1 by the court in September 2023. Rex Medical appealed, and the company cross-appealed; the company does not believe any losses from this matter would be material.
• In commercial litigation, Surgical Instrument Service Company, Inc. (SIS) filed antitrust claims related to EndoWrist service. The court found in the company's favor on all SIS's antitrust claims and stayed counterclaims in January 2025. SIS filed a notice of appeal in February 2025; the company is unable to make a reasonable estimate of loss.
• Three class action complaints, consolidated as 'In Re: da Vinci Surgical Robot Antitrust Litigation,' allege antitrust violations related to the service and repair of certain instruments. The court granted class certification in March 2025, and while some summary judgment rulings were made, the company is unable to make a reasonable estimate of loss or range of losses.
• Restore Robotics Repairs filed an antitrust complaint in September 2024 related to the service and replacement of X/Xi EndoWrist instruments. The company filed a motion to dismiss, and the plaintiff is seeking to file a second amended complaint; the company is unable to make a reasonable estimate of loss.

Related Party Transactions

• The company operates a majority-owned joint venture, Intuitive Surgical-Fosun Medical Technology (Shanghai) Co., Ltd. and Intuitive Surgical-Fosun (HongKong) Co., Ltd. (collectively, the Joint Venture), with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma). The noncontrolling interest in this joint venture is reflected as a separate component of consolidated stockholders' equity, and its share of earnings is presented separately in the Condensed Consolidated Statements of Comprehensive Income.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue and net income growth, increased share repurchase authorization, but potential negative impact from declining gross margins, increased operating expenses, and ongoing litigation risks.
• Customers (Hospitals/Healthcare Providers): Benefit from new product introductions (da Vinci 5, new instruments), expanded leasing options, and continued support for minimally invasive procedures. Face challenges from staffing shortages, cost pressures, and cautious capital spending, which could affect their ability to acquire systems or perform procedures.
• Patients: Benefit from advancements in minimally invasive care, new surgical systems and instruments, and expanded access to procedures. Potential risks from product liability issues or performance of remanufactured instruments.
• Employees: Benefit from share-based compensation plans and increased headcount, but may be impacted by operational adjustments due to macroeconomic factors or supply chain issues.
• Suppliers: Face potential challenges from tariffs and supply chain disruptions, with some possibly incurring incremental costs that may be passed on to the company.

Next Steps

• Complete the acquisition of da Vinci and Ion distribution businesses in Italy, Spain, Portugal, Malta, and San Marino in the first half of 2026.
• Seek European certification for the use of force feedback in the da Vinci 5 surgical system.
• Seek FDA clearances for additional indications for the da Vinci SP surgical system and expand its regulatory approvals in other OUS markets.
• Expand the da Vinci SP instrument offering over time.
• Seek additional clearances, approvals, and certifications for the Ion endoluminal system in OUS markets.
• Continue the rollout of the Ion system in China in a measured fashion, optimizing training pathways and collecting additional clinical data.
• Continue to make substantial investments in research and development, anticipating increased R&D expenses.
• Undertake capital investments ranging between $650 million and $725 million in 2025, primarily for facilities.
• Plan to adopt ASU 2023-09 during the fourth quarter of 2025 for its annual report.
• Monitor the outcome of SIS's brief due to the Ninth Circuit Court of Appeals by July 23, 2025.
• Monitor the impact of new U.S. tariff rates expected to take effect on August 1, 2025.

Key Dates

Recommendation

Intuitive Surgical demonstrated robust top-line growth with a 21% increase in total revenue and a 25% rise in net income for the quarter. Procedure volumes for both da Vinci and Ion systems saw significant increases, and the installed base continues to expand, indicating strong market adoption. The phased launch of the da Vinci 5 system and new product clearances are positive catalysts. However, gross profit margins declined due to higher costs associated with the da Vinci 5 launch, new tariffs, and increased fixed overhead. The company explicitly anticipates a 'significant increase in cost of revenues for the second half of 2025' due to tariffs. Furthermore, increased competition in China and ongoing macroeconomic pressures on hospital capital spending and staffing present headwinds. While the company's core business remains strong and innovative, these margin pressures and competitive dynamics warrant a cautious stance, suggesting a 'Hold' recommendation for investors to monitor the impact of these factors on future profitability.

Keywords

Robotic Surgery, Minimally Invasive Surgery, da Vinci Surgical System, Ion Endoluminal System, Medical Devices, Healthcare Technology, Surgical Instruments, SEC Filing, Quarterly Report, Financial Results, Procedure Growth, Installed Base, Tariffs, Supply Chain, Regulatory Clearances, Product Development, Litigation, ISRG